Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 6, 2020
Trial Information
Current as of September 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how lung cancer progresses in patients who are being treated with a type of immunotherapy called immune checkpoint inhibitors (ICIs). The researchers want to collect small samples of tumor tissue from patients when their cancer shows signs of worsening, or progression. By studying these samples, they hope to learn more about the biological changes that happen in lung cancer during treatment, which could help improve future therapies.
To participate in this trial, you need to be at least 18 years old and have been diagnosed with either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). You should have already received treatment with ICIs and experienced progression while on this treatment. If you choose to join, you will need to provide written consent and may undergo a minor procedure to obtain a tissue sample under local anesthesia. This study is currently recruiting participants, and it aims to provide valuable insights into lung cancer treatment and progression.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed NSCLC or SCLC;
- • Patient treated priorly by ICI and progressed under ICI;
- • Have provided written informed consent for the study;
- • Be \>/= 18 years of age on day of signing informed consent.
- Exclusion Criteria:
- • Patient under guardianship or curatorship;
- • Unable to provide written informed consent for the study;
- • Technical impossibility to carry out tissular rebiopsy under local anesthesia.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boulogne Billancourt, France
Patients applied
Trial Officials
Etienne Giroux Leprieur, MD, PhD
Principal Investigator
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials